{rfName}
Ra

Indexed in

License and use

Citations

173

Altmetrics

Grant support

This work was supported in part by grants from ISCIII-Fondos Feder (PI13/01574, ICI14/00372, CD14/0243, FI14/0264, CM13/0309, CES12/003, AC15/00038 and AC1500041) and Fundacion Investigacion y Educacion en SIDA (F-IES).

Analysis of institutional authors

De Mendoza, CarmenCorresponding Author

Share

June 15, 2023
Publications
>
Article
No

Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials

Publicated to:Antiviral Therapy. 22 (4): 307-312 - 2017-01-01 22(4), DOI: 10.3851/IMP3061

Authors: Arias, Ana; Aguilera, Antonio; Soriano, Vicente; Benitez-Gutierrez, Laura; Lledo, Gemma; Navarro, Daniel; Trevino, Ana; Otero, Esteban; Pena, Jose M; Cuervas-Mons, Valentin; de Mendoza, Carmen

Affiliations

Autonomous Univ, Madrid, Spain - Author
Conxo CHUS Hosp, Dept Internal Med, Santiago De Compostela, Spain - Author
Conxo CHUS Hosp, Santiago De Compostela, Spain - Author
La Paz Univ Hosp, Infect Dis Unit, Madrid, Spain - Author
Puerta de Hierro Res Inst, Dept Internal Med, Majadahonda, Spain - Author
Santiago Univ, Microbiol Dept, Santiago De Compostela, Spain - Author
Univ Hosp, Majadahonda, Spain - Author
See more

Abstract

Background: Cure rates above 90% have been reported in most Phase III clinical trials using distinct all-oral direct-acting antivirals (DAAs) in chronic hepatitis C patients. Preliminary results in real-world patients have confirmed this, although efficacy tends to be lower.Methods: All consecutive chronic hepatitis C patients treated with all-oral DAA regimens at three hepatitis clinics in Spain were retrospectively examined. Host and viral factors were tested as predictors of treatment failure.Results: A total of 363 chronic hepatitis C patients had completed a course of all-oral DAA therapy outside clinical trials up to the end of 2015. All but 14 (4%) patients achieved sustained virological response. There were 10 failures that occurred after 12 weeks of sofosbuvir-ledipasvir, despite 5 of them being on ribavirin. All failures but one were relapses. The only patient with viral breakthrough selected NS5B L159F and NS5A Y93H. In multivariate analyses, only advanced liver fibrosis (Meta-vir F3-F4) and HIV coinfection were significantly associated with treatment failure. A trend towards lower response was seen for HCV genotype 4.Conclusions: Treatment failures outside clinical trials are roughly seen in 4% of chronic hepatitis C patients who complete a course of all-oral DAA therapy, resembling what is seen in registration trials. In our series, outcomes were not significantly influenced by ribavirin addition, IL28B polymorphisms, HCV genotype, high baseline HCV RNA or prior interferon failure. However, advanced liver fibrosis and HIV coinfection were significantly associated with treatment failure. Our findings support that there is still room for individualization of current DAA therapy.

Keywords

Antiviral therapyChronic hepatitis-cCirrhosisDecompensationGenotype 1InfectionSofosbuvirTransient elastographyTreatment-naiveVirus-coinfected patients

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Antiviral Therapy due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2017, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Pharmacology. Notably, the journal is positioned en el Cuartil Q3 for the agency WoS (JCR) in the category Pharmacology & Pharmacy.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 2.08. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 12.95 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-20, the following number of citations:

  • WoS: 51
  • Google Scholar: 68

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-20:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 51.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 55 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.75.
  • The number of mentions on the social network X (formerly Twitter): 7 (Altmetric).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (DE MENDOZA FERNANDEZ, CARMEN).

the author responsible for correspondence tasks has been DE MENDOZA FERNANDEZ, CARMEN.